Alpha 2.0
Login Register
» Authors » Michael Fein

Michael Fein

Explore the profile of Michael Fein including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 14
Citations 94
Followers 0
Related Specialties
Allergy & Immunology
Gastroenterology
Dermatology
Top 10 Co-Authors
Moshe Ben-Shoshan
Faisal ALMuhizi
Ghislaine A C Isabwe
Christos Tsoukas
Ana M Copaescu
Ghislaine Annie C Isabwe
Florian Stehlin
Jason A Trubiano
Derek Lee
Rabea Y Khoudja
Published In
J Allergy Clin Immunol Pract
Front Allergy
Clin Exp Dermatol
Dig Dis Sci
Can J Gastroenterol Hepatol
Affiliations
Soon will be listed here.
Recent Articles
1.
Tolerance of penicillin V in patients with confirmed delayed hypersensitivity reactions to aminopenicillins
Alotaibi I, Khoudja R, Isabwe G, Fein M, Stehlin F, James F, et al.
J Allergy Clin Immunol Pract . 2024 Oct; 13(1):238-240.e1. PMID: 39454676
No abstract available.
2.
Successful treatment of chronic spontaneous urticaria using tralokinumab: a case report
Zhu C, Fein M, Ben-Shoshan M, Iannattone L, Netchiporouk E
Clin Exp Dermatol . 2024 Sep; 50(2):453-454. PMID: 39243384
No abstract available.
3.
Skin testing and challenge in patients with immediate hypersensitivity reactions to gadolinium-based contrast agents identify safe future options
Stehlin F, Khoudja R, Lee D, Toupin J, Isabwe G, Fein M, et al.
Allergol Int . 2024 May; 73(4):610-614. PMID: 38816288
No abstract available.
4.
Prevalence of omalizumab-resistant chronic urticaria and real-world effectiveness of dupilumab in patients with omalizumab-refractory chronic urticaria: a single-centre experience
Zhu C, BinJadeed H, Gabrielli S, Prosty C, Rahme E, Shand G, et al.
Clin Exp Dermatol . 2024 May; 49(10):1227-1231. PMID: 38723589
Chronic urticaria (CU) is characterized by weals (hives) angio-oedema (or both) that last for ≥ 6 weeks, with chronic spontaneous urticaria (CSU) being the most common subtype. Patients with omalizumab-refractory...
5.
COVID-19 booster vaccine acceptance following allergy evaluation in individuals with allergies
Stehlin F, Khoudja R, Al-Otaibi I, ALMuhizi F, Fein M, Gilbert L, et al.
J Allergy Clin Immunol Pract . 2023 Oct; 12(1):242-245.e2. PMID: 37802251
No abstract available.
6.
Efficacy of a Clinical Decision Rule to Enable Direct Oral Challenge in Patients With Low-Risk Penicillin Allergy: The PALACE Randomized Clinical Trial
Copaescu A, Vogrin S, James F, Chua K, Rose M, De Luca J, et al.
JAMA Intern Med . 2023 Jul; 183(9):944-952. PMID: 37459086
Importance: Fewer than 5% of patients labeled with a penicillin allergy are truly allergic. The standard of care to remove the penicillin allergy label in adults is specialized testing involving...
7.
Anaphylaxis induced by mRNA COVID-19 vaccines: follow-up and booster dose after previous desensitization
Alotaibi I, ALMuhizi F, Ton-Leclerc S, Fein M, Tsoukas C, Garvey L, et al.
Front Allergy . 2023 May; 4:1056619. PMID: 37207267
No abstract available.
8.
Reply to "Variability of eliciting thresholds in PEG allergy limits prediction of tolerance to PEG-containing mRNA COVID vaccines"
Picard M, Drolet J, Masse M, Filion C, ALMuhizi F, Fein M, et al.
J Allergy Clin Immunol Pract . 2022 Jul; 10(7):1933-1935. PMID: 35809994
No abstract available.
9.
Tolerance of the mRNA COVID-19 vaccines in patients with reported taxane reactions
Alenazy L, Hinther K, ALMuhizi F, Fein M, Tsoukas C, Ben-Shoshan M, et al.
J Allergy Clin Immunol Pract . 2022 Jun; 10(8):2169-2171.e2. PMID: 35690371
No abstract available.
10.
Allergic reactions to the coronavirus disease 2019 vaccine (ARCOV) study: The McGill University Health Centre experience
ALMuhizi F, Fein M, Gabrielli S, Gilbert L, Tsoukas C, Ben-Shoshan M, et al.
Ann Allergy Asthma Immunol . 2022 May; 129(2):182-188.e1. PMID: 35609744
Background: Messenger RNA coronavirus disease 2019 (COVID-19) vaccines have been associated with allergic reactions. A history of anaphylaxis has been suggested as a risk factor for such reactions. Polyethylene glycol...